 Tim Lahm
Concepts (463)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 55 | 2025 | 1741 | 9.960 |
Why?
| | Ventricular Dysfunction, Right | 22 | 2025 | 228 | 6.510 |
Why?
| | Ventricular Function, Right | 18 | 2025 | 276 | 3.920 |
Why?
| | Pulmonary Artery | 23 | 2023 | 1030 | 2.800 |
Why?
| | Hypoxia | 18 | 2024 | 1035 | 2.750 |
Why?
| | Estrogen Receptor alpha | 6 | 2024 | 134 | 2.500 |
Why?
| | Estradiol | 8 | 2021 | 497 | 2.320 |
Why?
| | Estrogens | 11 | 2023 | 354 | 2.000 |
Why?
| | Hypertrophy, Right Ventricular | 9 | 2023 | 133 | 1.650 |
Why?
| | Endothelial Cells | 9 | 2025 | 701 | 1.560 |
Why?
| | Bone Morphogenetic Protein Receptors, Type II | 3 | 2021 | 40 | 1.510 |
Why?
| | Pulmonary Embolism | 4 | 2023 | 208 | 1.480 |
Why?
| | Estrogen Receptor beta | 3 | 2018 | 35 | 1.370 |
Why?
| | Rats, Sprague-Dawley | 29 | 2024 | 2245 | 1.350 |
Why?
| | Familial Primary Pulmonary Hypertension | 10 | 2023 | 183 | 1.330 |
Why?
| | Vasoconstriction | 8 | 2008 | 186 | 1.330 |
Why?
| | Sex Characteristics | 10 | 2022 | 727 | 1.270 |
Why?
| | Lung | 13 | 2025 | 3752 | 1.180 |
Why?
| | Receptors, Estrogen | 4 | 2023 | 429 | 1.160 |
Why?
| | Gonadal Steroid Hormones | 7 | 2021 | 132 | 1.130 |
Why?
| | Nitric Oxide | 5 | 2021 | 886 | 1.100 |
Why?
| | Rats | 28 | 2024 | 5173 | 1.060 |
Why?
| | Ventricular Function, Left | 5 | 2019 | 528 | 1.050 |
Why?
| | Adaptation, Physiological | 4 | 2024 | 515 | 1.040 |
Why?
| | Animals | 65 | 2025 | 34600 | 1.030 |
Why?
| | Apelin | 3 | 2021 | 9 | 1.000 |
Why?
| | Ventricular Remodeling | 6 | 2023 | 258 | 0.960 |
Why?
| | Heart Failure | 8 | 2023 | 2158 | 0.960 |
Why?
| | Heart | 5 | 2020 | 639 | 0.930 |
Why?
| | Lung Diseases | 4 | 2025 | 723 | 0.850 |
Why?
| | Male | 60 | 2025 | 63202 | 0.780 |
Why?
| | Heart Ventricles | 9 | 2024 | 768 | 0.770 |
Why?
| | Humans | 82 | 2025 | 129128 | 0.770 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2018 | 257 | 0.760 |
Why?
| | Veterans | 6 | 2020 | 1419 | 0.730 |
Why?
| | Vascular Endothelial Growth Factor A | 11 | 2024 | 501 | 0.720 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2020 | 45 | 0.690 |
Why?
| | Ventricular Pressure | 7 | 2022 | 43 | 0.690 |
Why?
| | Disease Models, Animal | 17 | 2024 | 3953 | 0.680 |
Why?
| | Stenosis, Pulmonary Artery | 1 | 2020 | 4 | 0.680 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2020 | 90 | 0.680 |
Why?
| | Renin-Angiotensin System | 1 | 2020 | 80 | 0.680 |
Why?
| | Iron | 2 | 2021 | 283 | 0.650 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 201 | 0.640 |
Why?
| | Vascular Remodeling | 6 | 2025 | 181 | 0.630 |
Why?
| | Lung Injury | 2 | 2015 | 199 | 0.620 |
Why?
| | Cardiovascular System | 1 | 2020 | 139 | 0.620 |
Why?
| | Pulmonary Wedge Pressure | 2 | 2020 | 66 | 0.610 |
Why?
| | Telangiectasia, Hereditary Hemorrhagic | 1 | 2018 | 12 | 0.610 |
Why?
| | Hepatopulmonary Syndrome | 1 | 2018 | 24 | 0.600 |
Why?
| | Histamine H2 Antagonists | 1 | 2018 | 27 | 0.590 |
Why?
| | Sex Factors | 10 | 2025 | 1953 | 0.590 |
Why?
| | Neovascularization, Pathologic | 2 | 2017 | 291 | 0.580 |
Why?
| | Liver Diseases | 1 | 2021 | 285 | 0.580 |
Why?
| | Oxygen Inhalation Therapy | 2 | 2017 | 144 | 0.570 |
Why?
| | Bronchodilator Agents | 2 | 2017 | 245 | 0.560 |
Why?
| | Hyperoxia | 2 | 2015 | 87 | 0.560 |
Why?
| | Vascular Diseases | 1 | 2020 | 236 | 0.550 |
Why?
| | Up-Regulation | 4 | 2021 | 828 | 0.550 |
Why?
| | Female | 46 | 2025 | 68518 | 0.550 |
Why?
| | Myocardial Contraction | 3 | 2017 | 331 | 0.540 |
Why?
| | High-Intensity Interval Training | 1 | 2016 | 24 | 0.530 |
Why?
| | Intention | 1 | 2018 | 162 | 0.530 |
Why?
| | Reperfusion Injury | 4 | 2011 | 263 | 0.490 |
Why?
| | Research | 1 | 2018 | 410 | 0.480 |
Why?
| | Cell Hypoxia | 7 | 2018 | 229 | 0.470 |
Why?
| | Hemodynamics | 7 | 2022 | 1084 | 0.420 |
Why?
| | Blood Pressure | 4 | 2015 | 1735 | 0.410 |
Why?
| | Hypertension | 2 | 2021 | 1243 | 0.390 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2012 | 45 | 0.380 |
Why?
| | Whipple Disease | 1 | 2011 | 6 | 0.380 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 19 | 0.370 |
Why?
| | Embolism, Air | 1 | 2011 | 13 | 0.370 |
Why?
| | Magnesium Sulfate | 1 | 2011 | 18 | 0.370 |
Why?
| | Signal Transduction | 9 | 2020 | 4838 | 0.370 |
Why?
| | Pneumothorax | 1 | 2011 | 40 | 0.360 |
Why?
| | Calcium Channel Blockers | 1 | 2011 | 124 | 0.360 |
Why?
| | Leukapheresis | 1 | 2010 | 21 | 0.350 |
Why?
| | Pulmonary Medicine | 2 | 2024 | 80 | 0.350 |
Why?
| | Bradykinin | 1 | 2010 | 45 | 0.340 |
Why?
| | Pulmonary Circulation | 3 | 2023 | 416 | 0.340 |
Why?
| | Sepsis | 3 | 2010 | 557 | 0.330 |
Why?
| | Paracrine Communication | 6 | 2008 | 61 | 0.320 |
Why?
| | Aged | 14 | 2021 | 22090 | 0.310 |
Why?
| | Leukocytes | 1 | 2010 | 303 | 0.310 |
Why?
| | Myocardium | 5 | 2020 | 973 | 0.310 |
Why?
| | Calcium | 2 | 2012 | 1180 | 0.300 |
Why?
| | Blastomycosis | 1 | 2008 | 9 | 0.300 |
Why?
| | Acute Lung Injury | 1 | 2011 | 264 | 0.300 |
Why?
| | Altitude | 2 | 2024 | 447 | 0.290 |
Why?
| | Fellowships and Scholarships | 2 | 2024 | 275 | 0.290 |
Why?
| | Middle Aged | 15 | 2021 | 31080 | 0.270 |
Why?
| | Stroke Volume | 3 | 2020 | 590 | 0.270 |
Why?
| | Endothelins | 1 | 2007 | 59 | 0.270 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2007 | 91 | 0.270 |
Why?
| | Adult | 15 | 2024 | 35513 | 0.260 |
Why?
| | Cardiotonic Agents | 2 | 2021 | 124 | 0.260 |
Why?
| | Menstrual Cycle | 1 | 2007 | 124 | 0.260 |
Why?
| | Vascular Resistance | 2 | 2020 | 369 | 0.260 |
Why?
| | Administration, Inhalation | 2 | 2019 | 664 | 0.260 |
Why?
| | Monocrotaline | 3 | 2022 | 21 | 0.250 |
Why?
| | Neoplasms | 1 | 2020 | 2475 | 0.240 |
Why?
| | Calcium Signaling | 1 | 2007 | 235 | 0.240 |
Why?
| | Adrenal Cortex Hormones | 1 | 2008 | 519 | 0.230 |
Why?
| | Rats, Mutant Strains | 2 | 2021 | 24 | 0.230 |
Why?
| | Propionates | 2 | 2018 | 33 | 0.230 |
Why?
| | Myocardial Reperfusion Injury | 3 | 2010 | 121 | 0.220 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2007 | 431 | 0.220 |
Why?
| | Antihypertensive Agents | 2 | 2018 | 490 | 0.220 |
Why?
| | Databases, Factual | 2 | 2020 | 1279 | 0.220 |
Why?
| | Nitriles | 2 | 2018 | 161 | 0.220 |
Why?
| | Autophagy | 2 | 2016 | 267 | 0.210 |
Why?
| | Reproductive Health Services | 1 | 2023 | 16 | 0.210 |
Why?
| | United States | 12 | 2024 | 13940 | 0.210 |
Why?
| | Physical Conditioning, Animal | 2 | 2016 | 229 | 0.210 |
Why?
| | Myocytes, Cardiac | 3 | 2021 | 495 | 0.210 |
Why?
| | Double-Blind Method | 2 | 2019 | 1865 | 0.210 |
Why?
| | SOXF Transcription Factors | 2 | 2023 | 16 | 0.210 |
Why?
| | Aged, 80 and over | 7 | 2021 | 7066 | 0.200 |
Why?
| | Chloride Channels | 1 | 2023 | 38 | 0.200 |
Why?
| | Stem Cell Transplantation | 3 | 2008 | 165 | 0.200 |
Why?
| | Echocardiography | 2 | 2017 | 627 | 0.200 |
Why?
| | United States Department of Veterans Affairs | 2 | 2017 | 637 | 0.200 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2329 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 274 | 0.200 |
Why?
| | Chlorides | 1 | 2023 | 138 | 0.190 |
Why?
| | Mice | 13 | 2023 | 16644 | 0.190 |
Why?
| | Intercellular Signaling Peptides and Proteins | 3 | 2015 | 371 | 0.180 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2021 | 46 | 0.180 |
Why?
| | Menopause, Premature | 1 | 2021 | 9 | 0.180 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 153 | 0.180 |
Why?
| | Atrial Pressure | 1 | 2020 | 3 | 0.180 |
Why?
| | Metabolic Diseases | 1 | 2021 | 107 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 440 | 0.170 |
Why?
| | Phenylephrine | 3 | 2008 | 72 | 0.170 |
Why?
| | Cytokines | 5 | 2015 | 1987 | 0.170 |
Why?
| | Vasodilator Agents | 2 | 2013 | 322 | 0.170 |
Why?
| | Testosterone | 4 | 2014 | 379 | 0.170 |
Why?
| | Inflammation | 3 | 2024 | 2668 | 0.170 |
Why?
| | Receptors, Androgen | 1 | 2021 | 143 | 0.170 |
Why?
| | Hormones | 1 | 2021 | 140 | 0.170 |
Why?
| | Practice Guidelines as Topic | 2 | 2018 | 1493 | 0.170 |
Why?
| | Body Weight | 2 | 2015 | 932 | 0.170 |
Why?
| | Young Adult | 8 | 2021 | 12389 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 206 | 0.170 |
Why?
| | Models, Cardiovascular | 1 | 2021 | 190 | 0.170 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 4 | 2022 | 101 | 0.170 |
Why?
| | Mice, Knockout | 4 | 2021 | 2765 | 0.160 |
Why?
| | Ovariectomy | 4 | 2015 | 139 | 0.160 |
Why?
| | Drugs, Investigational | 1 | 2019 | 32 | 0.160 |
Why?
| | Organ Size | 1 | 2020 | 441 | 0.160 |
Why?
| | Vasoconstrictor Agents | 3 | 2008 | 128 | 0.160 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 515 | 0.160 |
Why?
| | Mesenchymal Stem Cell Transplantation | 3 | 2008 | 50 | 0.160 |
Why?
| | HLA-DP alpha-Chains | 1 | 2018 | 4 | 0.160 |
Why?
| | Propensity Score | 1 | 2020 | 265 | 0.160 |
Why?
| | Y Chromosome | 1 | 2018 | 8 | 0.160 |
Why?
| | Gender Identity | 1 | 2019 | 122 | 0.160 |
Why?
| | Animals, Newborn | 4 | 2015 | 805 | 0.150 |
Why?
| | Lipopolysaccharides | 4 | 2010 | 856 | 0.150 |
Why?
| | RNA, Messenger | 4 | 2021 | 2676 | 0.150 |
Why?
| | Troponin T | 1 | 2019 | 57 | 0.150 |
Why?
| | Respiratory Mucosa | 1 | 2021 | 306 | 0.150 |
Why?
| | Procollagen-Proline Dioxygenase | 1 | 2018 | 21 | 0.150 |
Why?
| | Metabolome | 1 | 2021 | 318 | 0.150 |
Why?
| | RNA, Long Noncoding | 1 | 2021 | 178 | 0.150 |
Why?
| | Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2018 | 20 | 0.150 |
Why?
| | Arterial Pressure | 2 | 2016 | 118 | 0.150 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2016 | 201 | 0.150 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 5 | 1 | 2018 | 21 | 0.150 |
Why?
| | HLA-DP beta-Chains | 1 | 2018 | 84 | 0.150 |
Why?
| | Adult Stem Cells | 2 | 2008 | 39 | 0.150 |
Why?
| | Oxygen Consumption | 2 | 2024 | 675 | 0.150 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2017 | 269 | 0.150 |
Why?
| | Isolated Heart Preparation | 1 | 2017 | 6 | 0.150 |
Why?
| | Bronchoscopy | 3 | 2021 | 208 | 0.150 |
Why?
| | Protein Stability | 1 | 2018 | 161 | 0.140 |
Why?
| | Risk Assessment | 4 | 2023 | 3260 | 0.140 |
Why?
| | bcl-2-Associated X Protein | 1 | 2017 | 48 | 0.140 |
Why?
| | Cardiac Output | 3 | 2015 | 155 | 0.140 |
Why?
| | Cells, Cultured | 6 | 2018 | 4010 | 0.140 |
Why?
| | Societies, Medical | 2 | 2018 | 749 | 0.140 |
Why?
| | Diastole | 1 | 2017 | 151 | 0.140 |
Why?
| | Peptide Fragments | 2 | 2019 | 686 | 0.140 |
Why?
| | Dietary Supplements | 1 | 2021 | 532 | 0.140 |
Why?
| | CD55 Antigens | 1 | 2016 | 28 | 0.140 |
Why?
| | Myocardial Infarction | 2 | 2019 | 1014 | 0.130 |
Why?
| | Pyrroles | 1 | 2017 | 192 | 0.130 |
Why?
| | Computed Tomography Angiography | 1 | 2017 | 115 | 0.130 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 231 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2017 | 235 | 0.130 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 340 | 0.130 |
Why?
| | Biomedical Research | 1 | 2022 | 647 | 0.130 |
Why?
| | Health Services Accessibility | 1 | 2023 | 897 | 0.130 |
Why?
| | Personnel Selection | 1 | 2017 | 74 | 0.130 |
Why?
| | Dyspnea | 1 | 2017 | 239 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 306 | 0.120 |
Why?
| | Women's Health | 1 | 2018 | 364 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2019 | 386 | 0.120 |
Why?
| | Research Report | 1 | 2016 | 73 | 0.120 |
Why?
| | Genetic Testing | 1 | 2018 | 427 | 0.120 |
Why?
| | Biological Assay | 1 | 2016 | 118 | 0.120 |
Why?
| | Golgi Apparatus | 1 | 2015 | 98 | 0.120 |
Why?
| | Stem Cells | 3 | 2008 | 579 | 0.120 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 249 | 0.120 |
Why?
| | Telemetry | 1 | 2015 | 40 | 0.120 |
Why?
| | Melanocytes | 1 | 2015 | 69 | 0.120 |
Why?
| | Physical Endurance | 1 | 2016 | 269 | 0.120 |
Why?
| | Physical Exertion | 1 | 2016 | 212 | 0.120 |
Why?
| | Pulmonary Blastoma | 1 | 2014 | 8 | 0.120 |
Why?
| | Macrophages | 1 | 2022 | 1466 | 0.120 |
Why?
| | Models, Biological | 6 | 2021 | 1695 | 0.120 |
Why?
| | Indoles | 1 | 2017 | 372 | 0.110 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2015 | 83 | 0.110 |
Why?
| | Health Policy | 1 | 2017 | 353 | 0.110 |
Why?
| | Treatment Outcome | 3 | 2016 | 10227 | 0.110 |
Why?
| | Familial Hypophosphatemic Rickets | 1 | 2014 | 6 | 0.110 |
Why?
| | Transcriptome | 1 | 2020 | 883 | 0.110 |
Why?
| | Chest Pain | 1 | 2014 | 89 | 0.110 |
Why?
| | Dehydroepiandrosterone | 1 | 2014 | 51 | 0.110 |
Why?
| | Apoptosis | 2 | 2015 | 2438 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1209 | 0.110 |
Why?
| | Splenectomy | 1 | 2013 | 58 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 384 | 0.110 |
Why?
| | Ovary | 1 | 2015 | 214 | 0.100 |
Why?
| | World Health Organization | 1 | 2013 | 110 | 0.100 |
Why?
| | Oxygen | 2 | 2015 | 902 | 0.100 |
Why?
| | Pulmonary Alveoli | 1 | 2015 | 366 | 0.100 |
Why?
| | Fever | 1 | 2014 | 301 | 0.100 |
Why?
| | Phosphates | 1 | 2014 | 168 | 0.100 |
Why?
| | Diagnosis, Differential | 2 | 2014 | 1417 | 0.100 |
Why?
| | Pulmonary Veins | 1 | 2014 | 93 | 0.100 |
Why?
| | Ischemia | 3 | 2015 | 395 | 0.100 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 171 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2011 | 1945 | 0.100 |
Why?
| | Myocardial Ischemia | 3 | 2008 | 249 | 0.100 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2015 | 261 | 0.100 |
Why?
| | Exercise | 1 | 2024 | 1950 | 0.100 |
Why?
| | ROC Curve | 1 | 2014 | 502 | 0.100 |
Why?
| | Length of Stay | 1 | 2017 | 1124 | 0.100 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 45 | 0.100 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2012 | 71 | 0.100 |
Why?
| | Mutation, Missense | 1 | 2014 | 318 | 0.100 |
Why?
| | Myocardial Perfusion Imaging | 1 | 2011 | 36 | 0.090 |
Why?
| | Mice, Inbred C57BL | 8 | 2019 | 5284 | 0.090 |
Why?
| | Airway Remodeling | 1 | 2012 | 58 | 0.090 |
Why?
| | Heart Arrest | 1 | 2015 | 328 | 0.090 |
Why?
| | Models, Animal | 2 | 2010 | 367 | 0.090 |
Why?
| | Healthcare Disparities | 1 | 2017 | 581 | 0.090 |
Why?
| | Oxidoreductases | 1 | 2011 | 90 | 0.090 |
Why?
| | Retrospective Studies | 4 | 2017 | 14571 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2015 | 416 | 0.090 |
Why?
| | Ceramides | 1 | 2011 | 104 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2008 | 1192 | 0.090 |
Why?
| | Asthma | 2 | 2021 | 2219 | 0.090 |
Why?
| | Endothelium, Vascular | 2 | 2007 | 872 | 0.090 |
Why?
| | Exercise Test | 2 | 2024 | 615 | 0.090 |
Why?
| | Acute Disease | 2 | 2010 | 968 | 0.090 |
Why?
| | Immunomodulation | 1 | 2010 | 89 | 0.080 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2024 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2015 | 1353 | 0.080 |
Why?
| | Angiopoietin-1 | 1 | 2009 | 11 | 0.080 |
Why?
| | Propofol | 1 | 2009 | 54 | 0.080 |
Why?
| | Immune System | 1 | 2010 | 177 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 3788 | 0.080 |
Why?
| | Coronary Artery Bypass | 1 | 2010 | 222 | 0.080 |
Why?
| | Rabbits | 1 | 2010 | 761 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 865 | 0.080 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2008 | 46 | 0.080 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2008 | 29 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 42 | 0.080 |
Why?
| | Hypnotics and Sedatives | 1 | 2009 | 154 | 0.080 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2008 | 83 | 0.070 |
Why?
| | Colorado | 1 | 2018 | 4396 | 0.070 |
Why?
| | Anesthesia | 1 | 2009 | 130 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 479 | 0.070 |
Why?
| | Positive-Pressure Respiration | 1 | 2008 | 75 | 0.070 |
Why?
| | Phenols | 1 | 2008 | 96 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 774 | 0.070 |
Why?
| | Embryonic Stem Cells | 1 | 2008 | 119 | 0.070 |
Why?
| | Ventricular Function | 1 | 2007 | 60 | 0.070 |
Why?
| | Steroids | 1 | 2008 | 148 | 0.070 |
Why?
| | Pyruvates | 1 | 2007 | 23 | 0.070 |
Why?
| | Pluripotent Stem Cells | 1 | 2008 | 78 | 0.070 |
Why?
| | Antifungal Agents | 1 | 2008 | 126 | 0.070 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2008 | 160 | 0.070 |
Why?
| | Education | 2 | 2018 | 100 | 0.070 |
Why?
| | Dihydrotestosterone | 1 | 2007 | 39 | 0.070 |
Why?
| | Nurses | 1 | 2009 | 164 | 0.070 |
Why?
| | Deferoxamine | 1 | 2007 | 18 | 0.070 |
Why?
| | Internship and Residency | 1 | 2017 | 1061 | 0.070 |
Why?
| | Iron Chelating Agents | 1 | 2007 | 17 | 0.070 |
Why?
| | Fibrosis | 2 | 2020 | 522 | 0.070 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2007 | 48 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 268 | 0.070 |
Why?
| | Homeostasis | 1 | 2010 | 605 | 0.070 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2009 | 319 | 0.070 |
Why?
| | Gastrointestinal Diseases | 1 | 2008 | 197 | 0.070 |
Why?
| | Carbon Dioxide | 1 | 2008 | 262 | 0.070 |
Why?
| | rho-Associated Kinases | 1 | 2007 | 83 | 0.070 |
Why?
| | Amino Acids, Dicarboxylic | 2 | 2016 | 8 | 0.070 |
Why?
| | Emphysema | 1 | 2007 | 95 | 0.070 |
Why?
| | Interleukin-6 | 2 | 2008 | 718 | 0.070 |
Why?
| | Epithelial Cells | 2 | 2016 | 1036 | 0.060 |
Why?
| | Hospitalization | 1 | 2016 | 2077 | 0.060 |
Why?
| | Androgens | 1 | 2007 | 174 | 0.060 |
Why?
| | Coronary Disease | 1 | 2008 | 384 | 0.060 |
Why?
| | Prospective Studies | 1 | 2017 | 7079 | 0.060 |
Why?
| | Body Mass Index | 1 | 2014 | 2266 | 0.060 |
Why?
| | Endothelin-1 | 1 | 2007 | 177 | 0.060 |
Why?
| | Gene Expression | 2 | 2021 | 1462 | 0.060 |
Why?
| | Inflammation Mediators | 1 | 2008 | 500 | 0.060 |
Why?
| | Pyrazoles | 1 | 2008 | 405 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 811 | 0.060 |
Why?
| | Risk Factors | 2 | 2021 | 9769 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 303 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2007 | 417 | 0.060 |
Why?
| | Embolectomy | 1 | 2023 | 13 | 0.060 |
Why?
| | NF-kappa B | 1 | 2008 | 652 | 0.050 |
Why?
| | Anti-Inflammatory Agents | 1 | 2007 | 471 | 0.050 |
Why?
| | Orchiectomy | 3 | 2008 | 65 | 0.050 |
Why?
| | Genetic Variation | 2 | 2018 | 934 | 0.050 |
Why?
| | HMGB Proteins | 1 | 2023 | 16 | 0.050 |
Why?
| | Thrombolytic Therapy | 1 | 2023 | 132 | 0.050 |
Why?
| | Thorax | 1 | 2022 | 41 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 83 | 0.050 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2007 | 375 | 0.050 |
Why?
| | Mechanotransduction, Cellular | 1 | 2023 | 111 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2017 | 5739 | 0.050 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 579 | 0.050 |
Why?
| | Aging | 2 | 2008 | 1772 | 0.050 |
Why?
| | Breath Tests | 1 | 2021 | 89 | 0.050 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2021 | 167 | 0.050 |
Why?
| | Fibrillar Collagens | 1 | 2020 | 14 | 0.040 |
Why?
| | Kallikreins | 1 | 2020 | 29 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2022 | 398 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2020 | 52 | 0.040 |
Why?
| | Incidental Findings | 1 | 2021 | 80 | 0.040 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2020 | 33 | 0.040 |
Why?
| | Vital Capacity | 1 | 2021 | 291 | 0.040 |
Why?
| | Biological Specimen Banks | 1 | 2021 | 96 | 0.040 |
Why?
| | United Kingdom | 1 | 2021 | 259 | 0.040 |
Why?
| | Cattle | 1 | 2023 | 962 | 0.040 |
Why?
| | Down-Regulation | 2 | 2016 | 634 | 0.040 |
Why?
| | Enzyme Activation | 2 | 2015 | 799 | 0.040 |
Why?
| | Mitochondria, Heart | 1 | 2020 | 92 | 0.040 |
Why?
| | Kinetics | 2 | 2015 | 1617 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2021 | 511 | 0.040 |
Why?
| | Ligands | 1 | 2021 | 614 | 0.040 |
Why?
| | NAD | 1 | 2020 | 71 | 0.040 |
Why?
| | Muscle, Skeletal | 2 | 2022 | 1640 | 0.040 |
Why?
| | Critical Care | 1 | 2023 | 544 | 0.040 |
Why?
| | Genotyping Techniques | 1 | 2018 | 72 | 0.040 |
Why?
| | Intensive Care Units | 1 | 2023 | 719 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5407 | 0.040 |
Why?
| | Cell Shape | 2 | 2008 | 55 | 0.040 |
Why?
| | Behavior | 1 | 2018 | 91 | 0.040 |
Why?
| | Curriculum | 1 | 2024 | 925 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 2 | 2008 | 33 | 0.040 |
Why?
| | Gene Expression Regulation | 1 | 2007 | 2508 | 0.040 |
Why?
| | RNA, Small Interfering | 2 | 2011 | 571 | 0.040 |
Why?
| | Sleep Apnea Syndromes | 1 | 2018 | 79 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 125 | 0.040 |
Why?
| | Clinical Competence | 1 | 2024 | 1021 | 0.040 |
Why?
| | Job Application | 1 | 2017 | 13 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 215 | 0.030 |
Why?
| | Comprehension | 1 | 2018 | 167 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2008 | 163 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 780 | 0.030 |
Why?
| | Proteomics | 1 | 2023 | 1010 | 0.030 |
Why?
| | Adolescent | 4 | 2021 | 20302 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2015 | 3184 | 0.030 |
Why?
| | Prolyl Hydroxylases | 1 | 2015 | 3 | 0.030 |
Why?
| | Gene Silencing | 1 | 2016 | 185 | 0.030 |
Why?
| | Prolyl-Hydroxylase Inhibitors | 1 | 2015 | 5 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2008 | 307 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2015 | 53 | 0.030 |
Why?
| | Cyclopentanes | 1 | 2015 | 19 | 0.030 |
Why?
| | Renal Circulation | 1 | 2015 | 57 | 0.030 |
Why?
| | Pulmonary Gas Exchange | 1 | 2015 | 117 | 0.030 |
Why?
| | Chloroquine | 1 | 2015 | 52 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1265 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 816 | 0.030 |
Why?
| | Age Factors | 2 | 2015 | 3120 | 0.030 |
Why?
| | Lysosomes | 1 | 2015 | 136 | 0.030 |
Why?
| | Proteolysis | 1 | 2015 | 162 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2015 | 145 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 593 | 0.030 |
Why?
| | Steroid Hydroxylases | 1 | 2014 | 22 | 0.030 |
Why?
| | Vitamin D3 24-Hydroxylase | 1 | 2014 | 15 | 0.030 |
Why?
| | Protein Folding | 1 | 2015 | 265 | 0.030 |
Why?
| | Gene Knock-In Techniques | 1 | 2014 | 52 | 0.030 |
Why?
| | Protein Transport | 1 | 2015 | 422 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 308 | 0.030 |
Why?
| | Complement Activation | 1 | 2016 | 365 | 0.030 |
Why?
| | Calcitriol | 1 | 2014 | 55 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 164 | 0.030 |
Why?
| | Creatinine | 1 | 2015 | 475 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 292 | 0.030 |
Why?
| | Glycolysis | 1 | 2015 | 293 | 0.030 |
Why?
| | Endoplasmic Reticulum | 1 | 2015 | 260 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2014 | 281 | 0.030 |
Why?
| | Phosphorylation | 2 | 2008 | 1687 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2015 | 579 | 0.020 |
Why?
| | Pyrimidines | 1 | 2015 | 445 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2018 | 1337 | 0.020 |
Why?
| | Research Design | 1 | 2017 | 1040 | 0.020 |
Why?
| | Computer Simulation | 1 | 2016 | 941 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 2 | 2008 | 872 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 2065 | 0.020 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2018 | 953 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2018 | 2739 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2267 | 0.020 |
Why?
| | Biosensing Techniques | 1 | 2011 | 114 | 0.020 |
Why?
| | Infant | 2 | 2017 | 8993 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 1943 | 0.020 |
Why?
| | Phenotype | 1 | 2018 | 3058 | 0.020 |
Why?
| | Quality of Life | 1 | 2021 | 2694 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3700 | 0.020 |
Why?
| | Child, Preschool | 2 | 2017 | 10451 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2015 | 1403 | 0.020 |
Why?
| | Short Bowel Syndrome | 1 | 2008 | 26 | 0.020 |
Why?
| | Enterocolitis, Necrotizing | 1 | 2008 | 35 | 0.020 |
Why?
| | Propanolamines | 1 | 2009 | 96 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2011 | 660 | 0.020 |
Why?
| | Endotoxins | 1 | 2009 | 216 | 0.020 |
Why?
| | Organ Specificity | 1 | 2008 | 291 | 0.020 |
Why?
| | Stromal Cells | 1 | 2008 | 105 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2009 | 172 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2008 | 73 | 0.020 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2008 | 85 | 0.020 |
Why?
| | Osteoblasts | 1 | 2008 | 126 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2007 | 108 | 0.020 |
Why?
| | Organ Culture Techniques | 1 | 2007 | 144 | 0.020 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2007 | 28 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 334 | 0.020 |
Why?
| | RNA Interference | 1 | 2008 | 441 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 204 | 0.020 |
Why?
| | Tibia | 1 | 2008 | 184 | 0.020 |
Why?
| | Administration, Oral | 1 | 2009 | 759 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2008 | 1044 | 0.020 |
Why?
| | Transfection | 1 | 2008 | 896 | 0.020 |
Why?
| | Femur | 1 | 2008 | 245 | 0.020 |
Why?
| | Diet | 1 | 2014 | 1204 | 0.020 |
Why?
| | Feasibility Studies | 1 | 2009 | 862 | 0.020 |
Why?
| | Thoracic Surgery | 1 | 2007 | 122 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2008 | 1271 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2541 | 0.010 |
Why?
| | Tissue Engineering | 1 | 2008 | 392 | 0.010 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2008 | 312 | 0.010 |
Why?
| | Blotting, Western | 1 | 2007 | 1169 | 0.010 |
Why?
| | Heart Diseases | 1 | 2007 | 347 | 0.010 |
Why?
| | Child | 2 | 2017 | 20806 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2011 | 2347 | 0.010 |
Why?
| | Glucose | 1 | 2009 | 983 | 0.010 |
Why?
| | Fibroblasts | 1 | 2008 | 939 | 0.010 |
Why?
| | Interleukin-1 | 1 | 2007 | 961 | 0.010 |
Why?
| | Fetus | 1 | 2007 | 760 | 0.010 |
Why?
| | Pregnancy | 1 | 2014 | 6375 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2737 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1901 | 0.010 |
Why?
| | Neurons | 1 | 2008 | 1456 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6518 | 0.010 |
Why?
|
|
Lahm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|